|Mr. Vincent J. Milano||Pres, CEO & Director||843.24k||N/A||1964|
|Mr. Louis J. Arcudi III||Principal Accounting Officer, Sr. VP of Operations, CFO, Treasurer & Assistant Sec.||490.54k||N/A||1961|
|Dr. Jonathan Yingling||Sr. VP & Chief Scientific Officer||N/A||N/A||1969|
|Mr. Robert Clayton Fletcher||Sr. VP of Bus. Devel. & Strategic Planning||513.24k||N/A||1963|
|Dr. Joanna C. Horobin||Sr. VP & Chief Medical Officer||N/A||N/A||1955|
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma; and which is in Phase Ib monotherapy trial in multiple tumor types for the treatment of refractory solid tumors, as well as IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. The company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastrointestinal disorders. In addition, it is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GlaxoSmithKline Intellectual Property Development Limited to license, research, develop, and commercialize pharmaceutical compounds from its nucleic acid chemistry technology for the treatment of selected targets in renal disease; Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.
Idera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2018 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 9; Compensation: 4.